Clinical trials: Lipid Disorders
Dyslipidemia
A Study of Evacetrapib in Participants With Abnormal Cholesterol
The main purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it when given once a day for 12, 24, and 52 weeks to participants with abnormal amounts of…
- Trial name
- NCT02168803
- Testing
- Evacetrapib
- Where
- 3 sites in United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hypertriglyceridemia
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to placebo in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 2000 mg/dL.
- Trial name
- MARINE (NCT01047683)
- Testing
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day
- Where
- 60 sites in United States, Denmark and 9 more
- Volunteers
- 229 people
- Sponsor
- Amarin Pharma Inc.
Hyperlipidemia
Ezetrol Post-Marketing Study
To compare the lipid lowering efficacy of adding ezetimibe to statin vs. statin alone.
- Trial name
- NCT00753883
- Testing
- simvastatin, Ezetimibe
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Dyslipidemia
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.
The purpose of the study is to assess the effect of AZD0780 on the pharmacokinetics of rosuvastatin, and to assess the safety and tolerability of AZD0780 single dose, in healthy participants administered alone and in combination…
- Trial name
- NCT05787002
- Testing
- AZD0780, Rosuvastatin
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Familial Hypercholesterolemia
Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
The main purpose of this study is to describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab when added to standard of care in children 10 to 17 years of age with familial hypercholesterolemia.
- Trial name
- HAUSER-OLE (NCT02624869)
- Testing
- Evolocumab
- Where
- 46 sites in United States, Australia and 21 more
- Volunteers
- 163 people
- Sponsor
- Amgen
Hypertension, Dyslipidemias
A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia
A Randomized, Double-blinded, Multi-center, Phase III Study to Compare The Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 versus HCP1701 in Patients with Hypertension and Dyslipidemia
- Trial name
- NCT04074551
- Testing
- HCP1701, Losartan, Amlodipine
- Where
- South Korea
- Volunteers
- 145 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension, Hyperlipidemia
CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)
The purpose of this study is to evaluate the drug-drug interaction of CKD-346(Telmisartan/S-Amlodipine, Rosuvastatin)
- Trial name
- NCT02047175
- Testing
- Telmisartan/S-Amlodipine, Rosuvastatin, Telmisartan/S-Amlodipine + Rosuvastatin
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Chronic Hepatitis B
Composite Probiotics Stabilize Lipid Metabolism in Chronic Hepatitis B Patients:A Clinical Trial
The goal of this is to verify the clinical efficacy of compound probiotics in reducing HBV infection levels and regulating intestinal flora in patients with chronic hepatitis B.
- Trial name
- NCT06221605
- Testing
- Probiotic
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Cerebrotendinous Xanthomatoses
Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid)
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Chenodeoxycholic acid capsules (250mg chenodeoxycholic acid) [dose: 1 x 02 capsules] versus Chenodeoxycholic acid leadiant…
- Trial name
- NCT06180057
- Testing
- Chenodeoxycholic acid, Chenodeoxycholic acid leadiant
- Where
- Jordan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Hypercholesteremia
Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy
The primary objective of the study is to compare the efficacy of rosuvastatin 10 mg with atorvastatin 10 mg by assessment of the percentage of subjects who reach EAS LDL-C target goals after 12 weeks of therapy.
- Trial name
- NCT00239330
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 26 sites in Belgium
- Volunteers
- 824 people
- Sponsor
- AstraZeneca
Metabolic Disease, Fabry Disease
Getting Global Rare Disease Insights Through Technology Study
This project is a randomized controlled trial to use a mobile health journal, called Zamplo (formerly known as MyHealthJournal or ZoeInsights), to record patient reported outcomes (PROM) in patients with metabolic disorders.
- Conditions
- Metabolic Disease, Fabry Disease, Gaucher Disease, Pompe Disease
- Trial name
- GRIT (NCT04758130)
- Testing
- Zamplo Digital Health Platform
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- M.A.G.I.C. Clinic LTD
Dyslipidemia
National Survey on Dyslipidemic Patients
The purpose of this observational study is to describe the time to lipid-lowering drug implementation in the management of dyslipidemic patients, according to the cardiovascular risk level.
- Trial name
- PRYSME (NCT00701402)
- Where
- 1,198 sites in France
- Volunteers
- 3,655 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants
This first-in-human (FIH) study of VXX-401, an anti-PCSK9 peptide-based immunotherapeutic candidate, is designed to assess the safety, tolerability, immunogenicity, and pharmacodynamics (PD) of VXX-401 and to determine an optimal…
- Trial name
- NCT05762276
- Testing
- VXX-401
- Where
- 5 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Vaxxinity, Inc.
Hypercholesterolemia
To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)
To evaluate the efficacy and safety of ezetimibe/simvastatin and niacin in patients with high cholesterol.
- Trial name
- NCT00271817
- Testing
- Comparator: ezetimibe/simvastatin + niacin (ER), Comparator: niacin (ER) tablet, Comparator: ezetimibe (+) simvastatin
- Volunteers
- 1,220 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin (SOLAR)
The purpose of this study is to compare the efficacy and safety of rosuvastatin with simvastatin and atorvastatin in reducing levels of low density lipoprotein cholesterol in subjects with hypercholesterolaemia
- Trial name
- SOLAR (NCT00654173)
- Testing
- Rosuvastatin, Simvastatin, Atorvastatin
- Volunteers
- 4,444 people
- Sponsor
- AstraZeneca
Hypertriglyceridemia
Efficacy and Safety Study of DHA-O in Adults With Hypertriglyceridemia
The purpose of this study is to investigate the efficacy and safety of DHA-O to lower elevated triglyceride levels in healthy adults with hypertriglyceridemia.
- Trial name
- DHA-O (NCT01737099)
- Testing
- DHA-O, Fish oil
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Sphingomyelin Lipidosis
Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency
Primary Objective: To evaluate the safety and tolerability of olipudase alfa administered intravenously in pediatric participants every 2 weeks for 64 weeks.
- Trial name
- ASCEND-Peds (NCT02292654)
- Testing
- Olipudase alfa
- Where
- 6 sites in United States, Brazil and 4 more
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Cardiovascular, Metabolic Disease
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
- Conditions
- Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder
- Trial name
- NCT07491172
- Testing
- CTX310
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 90 people
- Sponsor
- CRISPR Therapeutics AG
Hypertension, Hyperlipidemia
Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia
The purpose of this study is to evaluate efficacy and safety of coadministered Irbesartan and Atorvastatin in patients with hypertension and hyperlipidemia.
- Trial name
- NCT01442987
- Testing
- Irbesartan/Atorvastatin A, Irbesartan, Atorvastatin A
- Where
- South Korea
- Volunteers
- 230 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Obesity, Hyperlipidemia
A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia
The purpose of this study is to compare the efficacy and safety of daily topiramate versus placebo for the treatment of obese subjects with dyslipidemia.
- Conditions
- Obesity, Hyperlipidemia, Hypertriglyceridemia
- Trial name
- NCT00231621
- Testing
- topiramate
- Volunteers
- 179 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.